Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.

Journal of Neuro-oncology
Tobias BirnbaumAndreas Straube

Abstract

Rituximab improves outcome for patients with systemic diffuse large B-cell lymphoma (DLBCL) and has therefore become a standard component of the treatment of this disease. However, it is unclear whether rituximab is efficacious in patients with primary CNS lymphoma (PCNSL), a rare DLBCL variant, also. The purpose of this study was to evaluate the effect of rituximab on the complete response (CR) rate after chemotherapy with methotrexate (MTX) and ifosfamide (IFO) of patients with PCNSL. This is a retrospective, observational, single-center trial analyzing 36 consecutive patients with newly diagnosed, CD-20-positive PCNSL who were treated primarily with chemotherapy between March 2007 and December 2010. We compared 19 patients who were treated with MTX and IFO with 17 patients who were treated with the same regimen plus rituximab. The addition of rituximab to MTX and IFO was correlated with a significant increase in the CR rate (100.0 vs. 68.4 %, p = 0.02). Furthermore, six-month progression-free survival was significantly higher for the rituximab group (94.1 vs. 63.2 %, p = 0.04). Toxicity did not differ significantly between the groups. Our results indicate that rituximab might be efficacious in the treatment of PCNSL and supp...Continue Reading

References

Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L E AbreyL M DeAngelis
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Oct 24, 2002·Blood·James L RubensteinMarc A Shuman
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy BatchelorRegina Priet
Nov 5, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik PelsUwe Schlegel
Jun 2, 2005·Annals of Neurology·Ulrich HerrlingerUNKNOWN Neuro-Oncology Working Group of the German Society
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gaurav D ShahLauren E Abrey
Oct 28, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G IllerhausJ Finke
May 19, 2009·Lancet Neurology·Patrick G Morris, Lauren E Abrey
Sep 22, 2009·Lancet·Andrés J M FerreriUNKNOWN International Extranodal Lymphoma Study Group (IELSG)
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K FritschG Illerhaus
Mar 9, 2011·Neurology·T T BatchelorG J Lesser
Jan 10, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J WieduwiltJames L Rubenstein

❮ Previous
Next ❯

Citations

Aug 17, 2019·Hematological Oncology·Andreas M SchmittBenjamin Kasenda
Oct 9, 2019·Expert Review of Anticancer Therapy·Sabine Seidel, Uwe Schlegel
May 23, 2013·The American Journal of Dermatopathology·Tang Ngee ShimJoanna E Gach
Mar 19, 2013·Neuro-oncology·Gareth GregoryStephen Opat
Feb 28, 2014·British Journal of Haematology·Chen LossosIzidore S Lossos
Jun 28, 2014·Current Hematologic Malignancy Reports·Elizabeth H PhillipsKate Cwynarski
Sep 16, 2015·Current Opinion in Oncology·Andreas F HottingerKhê Hoang-Xuan
May 10, 2018·Leukemia & Lymphoma·Tarsheen K Sethi, Nishitha M Reddy
May 18, 2019·American Society of Clinical Oncology Educational Book·Andrés J M FerreriJames L Rubenstein
Aug 29, 2016·Journal of Experimental & Clinical Cancer Research : CR·Iole CordoneCarmine M Carapella
Sep 29, 2015·American Journal of Hematology·Roopesh KansaraDiego Villa
Sep 14, 2017·International Journal of Hematology·Yue SongMingzhi Zhang
Sep 2, 2015·Neurology·Ciara Marie KellySeamus O'Reilly
Dec 18, 2013·Current Treatment Options in Neurology·Patrick RothMichael Weller
Sep 16, 2015·Expert Opinion on Pharmacotherapy·Giovanni CitterioAndrés José Maria Ferreri
Mar 5, 2013·Current Treatment Options in Oncology·Stephane DoucetJeffrey Raizer
Apr 11, 2018·Expert Review of Neurotherapeutics·Giovanni CitterioAndrés J M Ferreri
Jul 1, 2020·Current Oncology Reports·Jacoline E C BrombergJeanette K Doorduijn
Jan 7, 2020·Journal of the Neurological Sciences·Pawan K Singh, Edward Pan
May 1, 2021·Cancers·Ruben Van DijckJacoline E C Bromberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.